Developments in urologic oncology “OncoForum”: The best of 2016

Conclusions In high-risk renal-cell carcinoma after nephrectomy, sunitinib has been considered as treatment choice. In localized prostate cancer, prostate-cancer-specific mortality was low irrespective of the treatment assigned (active monitoring, radical prostatectomy and external-beam radiotherapy). In metastatic castration-resistant prostate cancer new results of treatment with enzalutamide and abiraterone has been published, which have been shown beneficial effects in metastatic and no metastatic patients.
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research